93 related articles for article (PubMed ID: 2056769)
1. Breakpoint localization within the M-bcr and clinical course do not correlate in patients with chronic myelogenous leukemia undergoing alfa interferon therapy.
Opalka B; Wandl U; Beer U; Roggenbuck U; Kloke O; Niederle N
Leukemia; 1991 Jun; 5(6):452-6. PubMed ID: 2056769
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia.
Fioretos T; Nilsson PG; Aman P; Heim S; Kristoffersson U; Malm C; Simonsson B; Turesson I; Mitelman F
Leukemia; 1993 Aug; 7(8):1225-31. PubMed ID: 8350622
[TBL] [Abstract][Full Text] [Related]
3. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to alpha-interferon in chronic myelogenous leukemia.
Inoue T; Tojo A; Tsuchimoto D; Okamoto S; Ogura H; Tani K; Ozawa K; Shibuya M; Asano S
Leukemia; 1992 Sep; 6(9):948-51. PubMed ID: 1518306
[TBL] [Abstract][Full Text] [Related]
4. The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia.
Eisenberg A; Silver R; Soper L; Arlin Z; Coleman M; Bernhardt B; Benn P
Leukemia; 1988 Oct; 2(10):642-7. PubMed ID: 3172841
[TBL] [Abstract][Full Text] [Related]
5. Alpha interferon: perspectives in the biotherapy of chronic myelogenous leukemia.
Terebelo HR
Oncol Nurs Forum; 1991; 18(1 Suppl):5-9. PubMed ID: 1997975
[TBL] [Abstract][Full Text] [Related]
6. [Detection and localization of breakpoints within the first intron of the BCR gene in Ph1-positive leukemias].
Nakamura Y
Rinsho Ketsueki; 1991 Apr; 32(4):327-32. PubMed ID: 2067074
[TBL] [Abstract][Full Text] [Related]
7. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia.
Prejzner W
Med Sci Monit; 2002 May; 8(5):BR193-7. PubMed ID: 12011769
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
[TBL] [Abstract][Full Text] [Related]
9. The methylation status of the major breakpoint cluster region in human leukemia cells, including Philadelphia chromosome-positive cells, is linked to the lineage of hematopoietic cells.
Ohyashiki JH; Ohyashiki K; Kawakubo K; Tauchi T; Shimamoto T; Toyama K
Leukemia; 1993 Jun; 7(6):801-7. PubMed ID: 8501975
[TBL] [Abstract][Full Text] [Related]
10. The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia.
Tefferi A; Bren GD; Wagner KV; Schaid DJ; Ash RC; Thibodeau SN
Leukemia; 1990 Dec; 4(12):839-42. PubMed ID: 2173804
[TBL] [Abstract][Full Text] [Related]
11. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia.
Rozman C; Urbano-Ispizua A; Cervantes F; Rozman M; Colomer D; Féliz P; Pujades A; Vives Corrons JL
Leukemia; 1995 Jun; 9(6):1104-7. PubMed ID: 7596178
[TBL] [Abstract][Full Text] [Related]
13. M-BCR breakpoint location does not predict survival in Philadelphia chromosome-positive chronic myeloid leukemia.
Zaccaria A; Martinelli G; Buzzi M; Zuffa E; Zamagni MD; Testoni N; Russo D; Guerrasio A; Saglio G; Tura S
Haematologica; 1992; 77(1):16-20. PubMed ID: 1398276
[TBL] [Abstract][Full Text] [Related]
14. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.
Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S
Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454
[TBL] [Abstract][Full Text] [Related]
15. Therapy of chronic myelogenous leukaemia with interferons.
Talpaz M; Kurzrock R; Kantarjian H; Gutterman J
Cancer Surv; 1989; 8(4):793-8. PubMed ID: 2701727
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: a pilot study which raises important questions.
Ohyashiki K; Ohyashiki JH; Tauchi T; Fujieda H; Hojo H; Ohtaka M; Saito M; Nakazawa S; Toyama K
Leukemia; 1991 Jul; 5(7):611-4. PubMed ID: 2072747
[TBL] [Abstract][Full Text] [Related]
17. Mapping of breakpoints, and relationship to BCR-ABL RNA expression, in Philadelphia-chromosome-positive chronic myeloid leukaemia patients with a breakpoint around exon 14 (b3) of the BCR gene.
Mills KI; Sproul AM; Leibowitz D; Burnett AK
Leukemia; 1991 Nov; 5(11):937-41. PubMed ID: 1961034
[TBL] [Abstract][Full Text] [Related]
18. Further evidence that the site of the breakpoint in the major breakpoint cluster region (M-bcr) may be a prognostic indicator.
Mills KI; Hynds SA; Burnett AK; MacKenzie ED; Birnie GD
Leukemia; 1989 Dec; 3(12):837-40. PubMed ID: 2685475
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia, BCR/ABL transcript, response to alpha-interferon and survival. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
Leukemia; 1995 Oct; 9(10):1648-52. PubMed ID: 7564504
[TBL] [Abstract][Full Text] [Related]
20. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
